Reunion Neuroscience is an early-stage pharmaceutical company focused on the discovery and development of proprietary drug candidates designed to engage serotonergic receptors in the brain. The company aims to push the boundaries of neuroscience to create safer and more accessible therapeutics for millions of people whose mental health needs are not met by current treatments. Reunion Neuroscience operates in the pharmaceutical and biotechnology market, primarily serving patients suffering from depression and other mental health disorders. The business model involves extensive research and development (R&D) to create novel drug candidates, which are then brought to market through clinical trials and regulatory approval processes. Revenue is generated through the commercialization of these therapeutics, either directly or through partnerships and licensing agreements with larger pharmaceutical companies. The company is dedicated to transforming lives by making mental and emotional wellbeing the baseline for everyone.

Keywords: serotonergic receptors, mental health, depression, therapeutics, neuroscience, drug development, pharmaceutical, biotechnology, clinical trials, innovation.